In this bonus episode of Medication Talk, join us as we revisit our Notable New Meds of 2025 webinar and highlight two medications that didn’t make it into the main podcast—both newly approved antibiotics with important implications for clinical practice.

Listen in as our editors take a deeper look at:

• Gepotidacin (Blujepa) for uncomplicated urinary tract infections
• Aztreonam/avibactam (Emblaveo) for complicated intraabdominal‑abdominal infections

You’ll hear practical insights into where these therapies fit in current treatment approaches, what safety and interaction issues to watch for, and why they matter when resistance limits your options—giving you more confidence when either of these new meds show up in your practice.

**No CE Credit is available for this bonus episode.**

Use code mt1026 at checkout for 10% off a new or upgraded subscription.

******

TRC Healthcare Editors: 

• Sara Klockars, PharmD, BCPS
• Stephen Small, PharmD, BCPS, BCPPS, BCCCP, CNSC 

None of the speakers have anything to disclose. 

This podcast is an excerpt from one of TRC’s monthly live CE webinars, the full webinar originally aired in December 2025. 

The clinical resources related to this podcast are part of a subscription to Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights: 

• Chart: Urinary Tract Infections
• Chart: Aztreonam-avibactam (Emblaveo)
• Article: Keep Boosting Antibiotic Stewardship for Complicated UTIs

Send a text

*****

📣 New Podcast!📣

🌱Natural Medicines: Evidence in Practice 

Evidence, not hype. Concise, clinician‑ready guidance on natural medicines and integrative care. Episode 1: GLP‑1s & Nutrition is live now!

*****

Email us: [email protected].

The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.

Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.

Learn more about our product offerings at trchealthcare.com.